Opus Genetics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
from Jean Bennett, that are all gene augmentation using known vectors, going after different types of inherited retinal degenerations, that potentially show improvement of vision. What you will see in our dataset is we like to always try to show improvement of function, not just preservation of vision. We have our most advanced program is called LCA5. It is by far, but 10x our smallest indication. But it is right in the middle of the pivotal trial. That trial will read out next year with potential BLA filing next year if the data holds. BEST1 is a really interesting story. It is our next pipeline program that we will talk about in some detail, but much larger indication at 23,000 or so patients. We have proof of concept data and a low-dose early cohort with an additional cohort coming in Q1.
We also are about to be dosing patients in two additional mutations, one called RDH12, which is about 10 times the size of a LUXTURNA. It is 2,500 or so patients. MERTK is about the same epidemiology. Both of those are more visual cycle type programs that we are excited to be treating patients in now.
Got it. The BEST1 clinical data that were reported earlier this year, obviously from the low-dose cohort, I think it surprised people not just with the data, but the fact that you had alignment with the FDA when you put out the data. The guessing game was off.
Yes. Right. Can you sort of talk to that dataset?
Because I think initially there was the expectation of the subretinal fluid.
But then you had something much more remarkable than just the subretinal fluid.
So Best vitelliform macular dystrophy is really characterized by the presence of vitelliform material. And vitelliform material is lipofuscin or byproducts of the visual cycle and working photoreceptors that is not transported into the circulatory system for disposal in patients who are missing the bestrophin channel. And so fundamentally, the holy grail for this disease is to replace the bestrophin channel and remove the vitelliform material. And that's exactly what we showed in at least two of our BVMD patients in cohort one. Interestingly enough, the coolest part of the dataset for me is that the retinal sensitivity in exactly those same areas dramatically improved. And so the vitelliform material is really a marker of where you have rescuable photoreceptors. And those photoreceptors, when you do rescue them by removing the vitelliform material, the sensitivity improves quite dramatically.
If we had just taken those loci where the vitelliform material was, we would have seen about a 4.5 or so decibel improvement on microperimetry. And as you guys know from the literature, three decibels is the improvement is equivalent of 15 letters on an eye chart. So really dramatic improvement in function of the retina. Now, the subretinal fluid, these patients in cohort one were end-stage patients with kind of a lake of subretinal fluid with the vitelliform material around the periphery of it. And the subretinal fluid did not change, and I think that's a characteristic of the fact that there is very little viable photoreceptors in that subretinal fluid. I think that's kind of like a central graveyard for the retina.
And that was really elucidated by an Italian study that was published in early September, where they showed the natural history of 13 patients over five years. And what they showed was in the area of central fluid, it doesn't really change. Everything just kind of stays the same. But each year, the area where the vitelliform material is, they call it a transitional zone, that area decreases on average by a half a decibel. No patient got better. They all decreased. And the fluid would just kind of circumferentially get bigger each year. And so I think that the vitelliform material is kind of just where the action is in these patients. What we're going to see in cohort two is much more early-stage patients. And so it's going to be a little bit different because of that than what we saw in cohort one.
For that reason, I am pretty excited.
It is also a higher dose cohort.
It is about three times the dose. Yeah. It is a much higher dose.
Yeah. Yeah. I mean, that is the interesting thing about when you think about the pipeline, you can go after loss of function mutations.
which maybe is easier not to crack.
But then to sort of address dominant negative mutations like you did with Yes BEST.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
